Of the cancer patients who are treated with chemotherapy, approximately 50% receive a Pt^II^ drug such as cisplatin, carboplatin or oxaliplatin.[@cit1] However, the side-effects of treatment with Pt^II^ drugs can be severe, and the development of resistance can also be a serious problem.[@cit2] Octahedral low-spin 5d^6^ Pt^IV^ prodrugs are more kinetically inert than their Pt^II^ counterparts, and have the potential to address these issues.[@cit3]--[@cit6] Both redox-activatable[@cit7],[@cit8] and photo-activatable[@cit9]--[@cit12] Pt^IV^ prodrugs can exhibit promising pharmacological properties and can also incorporate ligands which - when released upon reduction of Pt^IV^ to Pt^II^ -- exert an anti-cancer effect through mechanisms of action which are different from those of established Pt^II^-based drugs.[@cit5],[@cit13]

Whilst the photochemistry of Pt^IV^ diazido complexes has been extensively investigated, Pt^IV^ monoazido complexes are less well explored. It was not known if two azido groups are necessary for photoreduction to Pt^II^, and what products were likely to be formed under irradiation. Direct derivation of a Pt^IV^ diazido complex was anticipated to be an effective way to answer these questions. Cycloaddition (click) reactions of metal azido complexes are well-established[@cit14] -- although mostly for Pt^II^ rather than Pt^IV^. We recently reported the first Pt^IV^ triazolato monoazido complexes; synthesised *via* click reactions of Pt^IV^ azido complexes with both electron-deficient (*e.g.* 1,4-diphenyl-2-butyne-1,4-dione)[@cit15] and strained alkynes (*e.g.* DBCO; dibenzocyclooctyne-amine).[@cit16] Due to the popularity of click chemistry, a range of 1,2,3-triazoles with potential biomedical applications have been reported;[@cit17]--[@cit19] 1,2,3-triazoles have the potential to participate in C--H hydrogen bonding; behave as hydrogen bond donors through both non-coordinated N-atoms; act as intercalating agents *via* π--π stacking and substitute for amides; making them attractive ligands.[@cit20] Pt^II^ triazole complexes[@cit21] and triazolato-bridged Pt^II^ complexes have been shown to demonstrate promising anti-cancer activity.[@cit22]

Strain-promoted azide--alkyne \[3+2\] cycloaddition (SPAAC) exploits the spontaneous reactivity of cyclooctynes and azides due to inherent ring strain in the cyclooctyne.[@cit23] It can be used to assemble constructs under mild conditions for both biological (*e.g.* vascularly-targeted radiolabelled liposomes,[@cit24] glycan imaging[@cit25] and glycocalyx selective editing[@cit26]) and chemical (*e.g.* Ru azido DBCO[@cit27] and Pt^II^-DBCO fluorophore[@cit28]) applications.

The Sondheimer diyne (5,6,11,12-tetradehydrodibenzo\[*a*,*e*\]cyclooctene) (**2**) ([Scheme 1](#sch1){ref-type="fig"}) is a strained diyne which is straightforward to synthesise. It has been used as a monomer in Mo-catalysed ring-opening alkyne metathesis polymerization reactions[@cit29] and to couple together Ag([i]{.smallcaps}) species[@cit30] and biomolecules.[@cit31] For our purposes, it enables the union of two -- potentially different -- Pt^IV^ azido complexes under catalyst-free conditions, without interaction of either Pt^IV^ centre with any other functional groups on the newly formed 1,2,3-triazole ligands -- something which has complicated our earlier studies.[@cit15],[@cit16] Di-nuclear Pt^IV^ complexes are promising since they can be used to deliver multiple different biologically active agents to cancer cells.[@cit8] Here we report the facile, catalyst-free assembly of the water-soluble, water-stable, di-nuclear Pt^IV^ 1,2,3-triazolato azido complex **3-\[N1,N3\]** and our investigations into its photochemical properties ([Scheme 1](#sch1){ref-type="fig"}).

![Synthesis of Pt^IV^ triazolato azido complex **(3)-\[N1,N3\]**.](c9cc05310g-s1){#sch1}

Diyne (**2**) was synthesised according to literature reports and purified by column chromatography (ESI[†](#fn1){ref-type="fn"}).[@cit32],[@cit33] *trans*,*trans*,*trans*-\[Pt(N~3~)~2~(OH)~2~(py)~2~\] (**1**) was synthesised and purified by HPLC.[@cit34] The reaction between **1** (200 mg, 0.42 mmol) and **2** (30 mg, 0.15 mmol, 0.4 eq.) in MeCN (150 ml) at room temperature was monitored by LCMS and was judged to be complete after 2d. No mono-Pt^IV^ cycloaddition intermediates were detected by ESI-MS during the course of the reaction. This is consistent with DFT calculations of the reactivity profile of **2**, which indicate that the activation energy for the second cycloaddition is lower than for the first, due to the highly distorted alkyne bond in the mono-substituted intermediate, arising from steric repulsion between the substituent on the triazole ring and the hydrogen atom on the benzene ring.[@cit31] The reaction solution was dilute, minimising the formation of Pt^IV^ oligomers (see Fig. S1, ESI[†](#fn1){ref-type="fn"}) due to potential reactivity of the second Pt^IV^-azido ligand.

The major product (**3**) was detected by LCMS, as both \[**3** + H\]^+^ (1143.20 *m*/*z*) and \[**3** + Na\]^+^ (1165.36 *m*/*z*) adducts. Complex **3** was isolated by mass-directed LCMS as a mixture of two regioisomers: **3-\[N1,N3\]** and **3-\[N3,N3\]** (Fig. S2, ESI[†](#fn1){ref-type="fn"}). HPLC re-injection confirmed the isomers co-eluted with a purity of 95% (Fig. S3, ESI[†](#fn1){ref-type="fn"}). Following solvent removal and reconstitution of the pale yellow solid in *d*~3~-MeCN, ^1^H NMR spectroscopy indicated that **3-\[N1,N3\]** -- which has two-fold symmetry -- was the major isomer present. This is consistent with the previously reported reaction of **2** with excess benzyl azide which resulted in a 60% \[N1,N3\]: 38% \[N1,N1\] product distribution.[@cit31] Yellow crystals of **3-\[N1,N3\]** rapidly formed from the solution of regioisomers in *d*~3~-MeCN, on standing for 24 h.

Recrystallisation from MeCN afforded X-ray crystallographic quality crystals of **3-\[N1,N3\]** ([Fig. 1](#fig1){ref-type="fig"}), confirming \[N1,N3\] Pt^IV^-triazole coordination and revealing the ligand interactions around the puckered chair of the cyclooctene ligand. Distances between pyridine, triazole and benzene groups are shown in Fig. S4--S6 (ESI[†](#fn1){ref-type="fn"}); the pyridine ligands undergo π--π interactions with the cyclooctene ring ranging from 3.527--4.509 Å in length. A hydrogen-bond interaction of 2.178(3) Å was observed between Pt(1)--OH(2) and triazole N(2); the corresponding hydrogen-bond interaction on the other side of the molecule measured 2.242 Å (Pt--OH(3) to triazole N(5)). The identity of **3** was also confirmed by HRMS \[**3** + H\]^+^ (C~36~H~32~N~16~O~4~Pt~2~H): 1143.2123 *m*/*z* found; 1143.2069 *m*/*z* calcd (Fig. S7, ESI[†](#fn1){ref-type="fn"}).

![X-ray crystallographic structure of **3-\[N1,N3\]** with thermal ellipsoids displayed at 50% probability.[@cit35] Selected bond lengths (Å): Pt1--N3: 2.060(2), Pt1--N7: 2.041(3), N7--N8: 1.219(4), N8--N9: 1.151(5). Pt1--O2: 2.002(2). Selected angles (°): Pt1--N7--N8: 114.1(2); N7--N8--N9: 174.5(4). (See Tables S1--S3, ESI[†](#fn1){ref-type="fn"}).](c9cc05310g-f1){#fig1}

Collision-induced dissociation (MS/MS) experiments of \[**3-\[N1,N3\]** + H\]^+^ demonstrated that at low collision energies the complex readily fragmented through loss of OH and N~3~ ligands, to give stable species \[**3-\[N1,N3\]**--N~3~OH + H\]^+^ (1083.32 *m*/*z*) and \[**3-\[N1,N3\]**--2(N~3~OH)\]^+^, (1023.30 *m*/*z*), consistent with our previous observations of azido ligand loss during MS/MS fragmentation of **1**.[@cit34] Stable mono-Pt fragments were also observed, including \[Pt(C~16~N~6~H~7~)N~3~\]^+^ (520.15 *m*/*z*) resulting from ejection of several small ligands and one Pt fragment from the central cyclooctene ligand, as well as smaller fragments including (\[Pt(py)~2~(OH)~2~\]^+^ (387.12 *m*/*z*)) (\[Pt(py)~2~(OH)\]^+^ (370.11 *m*/*z*)) and (\[Pt(Py)~2~\]^+^ (352.10 *m*/*z*)) demonstrating cleavage of the Pt--triazole bond (Fig. S7, ESI[†](#fn1){ref-type="fn"}).

Complex **3-\[N1,N3\]** was fully characterised by ^195^Pt, ^1^H and ^13^C NMR spectroscopic methods. ^1^H NMR spectroscopy revealed four different phenyl environments; a 2D ^1^H TOCSY experiment was used to determine the complete spin systems and to obtain coupling constants for overlapping signals (Fig. S9, ESI[†](#fn1){ref-type="fn"}) and 1D NOESY experiments revealed nOe interactions between pyridine (H~o~) and phenyl ring (H~A~) protons, confirming the regiochemistry of the product (Fig. S10, ESI[†](#fn1){ref-type="fn"}). ^13^C NMR spectral assignment (Fig. S11, ESI[†](#fn1){ref-type="fn"}) was aided by ^1^H--^13^C HSQC and HMBC experiments. Complex **3-\[N1,N3\]** gave rise to a single ^195^Pt NMR spectral resonance at 723 ppm (*d*~3~-MeCN, Fig. S12-top, ESI[†](#fn1){ref-type="fn"}).

Whilst **3-\[N1,N3\]** is stable in both *d*~3~-MeCN and D~2~O for a period of at least 5 weeks as judged by ^1^H NMR spectroscopy, the resonances change position markedly in the different solvents. Solvent removal from a sample of **3-\[N1,N3\]** in *d*~3~-MeCN followed by reconstitution in D~2~O resulted in an overall 163 ppm upfield shift in ^195^Pt NMR resonance from 723 ppm (*d*~3~-MeCN) to 857 ppm (1 : 1 *d*~3~-MeCN : D~2~O) to 886 ppm (D~2~O, Fig. S12-bottom, ESI[†](#fn1){ref-type="fn"}). In the ^1^H NMR spectrum (D~2~O), the H~A′~ and H~B′~ protons of the benzene rings no longer superimposed on the pyridyl H~m~ resonances (Fig. S13 and S14, ESI[†](#fn1){ref-type="fn"}). Consistent with this, the ^195^Pt NMR resonance of **1** also changes by 164 ppm on changing solvent from *d*~3~-MeCN (778 ppm, this work) to D~2~O (942 ppm).[@cit34] Selective ^1^H NOESY NMR experiments on **3-\[N1,N3\]** (D~2~O) revealed the same nOe correlations which were observed in *d*~3~-MeCN, with dissolution in 1 : 1 MeCN/D~2~O showing ^1^H NMR resonances at intermediate chemical shifts (Fig. S14-middle, ESI[†](#fn1){ref-type="fn"}), indicating that the change is unlikely to be due to a formal N1--N2 Pt--triazole rearrangement in D~2~O -- a possibility for metal triazole complexes which we wanted to rule out.[@cit27],[@cit36],[@cit37]

IR spectroscopy of a *d*~3~-MeCN sample of **3-\[N1,N3\]** (Fig. S15, ESI[†](#fn1){ref-type="fn"}) showed a strong *ν*~asym~N~3~ stretch at 2043 cm^--1^; slightly lower than observed for **1** (2051 cm^--1^, solid).[@cit38] The UV-Vis spectrum of **3-\[N1,N3\]** showed a long shoulder with *λ*~max~*ca.* 254 nm tailing into the visible region corresponding to the N~3~ → Pt LMCT transition band, with increased intensity at shorter wavelengths compared to **1** due to the additional aromatic groups (Fig. S16, ESI[†](#fn1){ref-type="fn"}).

A D~2~O (1 ml) solution of complex **(3)-\[N1,N3\]** (5.6 mg) and the DNA model 5′-GMP (2 eq. 4.8 mg) was irradiated (*λ*~irr~ 452 nm) with regular monitoring by LCMS and ^1^H NMR spectroscopy. Both Pt^IV^ and Pt^II^ photoproducts were detected by LCMS including non-5′-GMP bound species (where M = **3-\[N1,N3\]**): \[M--N~3~\]^+^ at 1100.12 *m*/*z*; \[M--H~2~O~2~ + H\]^+^ at 1109.12 *m*/*z*; \[**3-\[N1,N3\]**--N~3~OH + H^+^\]^+^ 1084.05 *m*/*z*. The cyclic-5′-GMP species \[Pt^II^(OH)(py)~2~(N~5~C~10~O~7~H~12~P)\]^+^ was observed at 715.14 *m*/*z*, although -- unlike for similar investigations with complex **1** -- no evidence of \[Pt(OH)(py)~2~(5′-GMP)\]^+^ was observed (predicted 733.1097 *m*/*z*). The LCMS *m*/*z* range is limited to 1250 *m*/*z* and a different ESI-MS instrument was therefore used to detect the presence of higher mass species, including the Pt^II^*bis*-GMP adduct: \[M--2(H~2~O~2~)--2N~3~ + 2(5′-GMP) + Na\]^+^ at 1739.85 *m*/*z*. (Fig. S17, ESI[†](#fn1){ref-type="fn"}).

The photochemistry was also monitored by ^1^H--^195^Pt HMBC and 1D ^195^Pt NMR spectroscopy (**(3)-\[N1,N3\]** 22 mM; 5′-GMP 46 mM, 1 : 1 D~2~O : *d*~3~-MeCN, *λ*~irr~ 452 nm, 180 min). During irradiation, the intensity of the ^195^Pt NMR spectroscopic resonance corresponding to **(3)-\[N1,N3\]** (854 ppm) decreased, with small amounts of new Pt^IV^ species (1267, 1350 ppm) and two more intense Pt^II^ signals appearing (--2224 ppm and --2369 ppm; Fig. S18 and S19, ESI[†](#fn1){ref-type="fn"}). These spectra were consistent with the formation of multiple Pt^II^ and Pt^IV^ photoproducts, as observed by LCMS (for discussion see end of ESI[†](#fn1){ref-type="fn"}).

Irradiation of a solution of **3-\[N1,N3\]** (1.15 mM) and 5,5-dimethyl-1-pyrroline *N*-oxide (DMPO, 20 mM) monitored by EPR spectroscopy in either water or cell-free lysate (KNS42) generated azidyl (N~3~˙) and hydroxyl (OH˙) radical species, trapped in a 85 : 15 and 90 : 10 molar ratio, respectively (Fig. S20(a), ESI[†](#fn1){ref-type="fn"} and [Fig. 2(a)](#fig2){ref-type="fig"}), with a maximum trapped radical concentration of 7 μM. The signals started to decay after ∼30 min irradiation (Fig. S23(a), ESI[†](#fn1){ref-type="fn"} and [Fig. 2(b)](#fig2){ref-type="fig"}). The inclusion of 5′-GMP in the solution of **3-\[N1,N3\]** in lysate had a significant effect; the maximum trapped radical concentration reduced to 3 μM with a 95 : 5 N~3~˙ : OH˙ molar ratio (Fig. S22(a), ESI[†](#fn1){ref-type="fn"}) and radical trapping slowed down (Fig. S25(a), ESI[†](#fn1){ref-type="fn"}). These experiments were repeated with complex **1** (Fig. S20(b), S21(b) and S22(b), ESI[†](#fn1){ref-type="fn"}) which released almost no hydroxyl radicals, reaching a much higher trapped radical maximum concentration of 32 μM in water and lysate. The rise and decay of the signal was faster (Fig. S23(b) and S24(b), ESI[†](#fn1){ref-type="fn"}) in comparison to **3-\[N1,N3\]**, consistent with **1** having a greater absorbance at the wavelength of irradiation. The effect of including 5′-GMP in the lysate solution of complex **1** was less pronounced (Fig. S22(b) and S25(b), ESI[†](#fn1){ref-type="fn"}) than for **3-\[N1,N3\]**, with only a slightly lower maximum trapped radical concentration (28 μM) and slower kinetics in the presence of 5′-GMP. Minimal radical release was observed in the absence of irradiation in aqueous solution, consistent with the observed stability of **3-\[N1,N3\]** and **1** (Fig. S26, ESI[†](#fn1){ref-type="fn"}). Irradiation of controls (DMPO, and 5′-GMP + DMPO) in lysate did not result in any trapped radicals (Fig. S27, ESI[†](#fn1){ref-type="fn"}).

![X-band cw-EPR spectrum (a) showing trapping of azidyl (N~3~˙) and hydroxyl (OH˙) radicals (1.15 mM **(3)-\[N1,N3\]** + 20 mM DMPO spin-trap) in freshly prepared KNS42 lysate (*λ*~irr~ 440--480 nm; spectra averaged over 1 h of maximum signal intensity); (b) fitted spectrum with 90% DMPO-N~3~ and 10% DMPO-OH (red line). The kinetic profile (b) for the total radical adduct signal (black) has been deconvoluted into the DMPO-N~3~ (blue) and DMPO-OH (red) contributions.](c9cc05310g-f2){#fig2}

To conclude, we have demonstrated an effective method for joining together two Pt^IV^ azido complexes to give the di-nuclear Pt^IV^ triazolato azido complex **3-\[N1,N3\]** which is soluble and stable in aqueous solution for at least 5 weeks. Irradiation of **3-\[N1,N3\]** with visible light (*λ*~irr~ 452 nm) in the presence of 5′-GMP results in the formation of new Pt^IV^ and Pt^II^ species as well as radical species (N~3~˙, OH˙) in both H~2~O and cell-free lysate. Whilst the presence of two Pt-azido groups in complex **1** predominantly favours photochemical release of azido radicals, **3-\[N1,N3\]** undergoes photoreduction to Pt^II^ with the production of a greater proportion of hydroxyl radicals, consistent with the Pt^IV^ monoazido structure. Radical -- particularly OH˙ -- trapping from **3-\[N1,N3\]** was affected to a greater extent by the presence of 5′-GMP, in contrast to irradiation of **1**. It has previously been shown that N~3~˙ produced by irradiation of **1** can be quenched by [l]{.smallcaps}-tryptophan (Trp),[@cit39] forming Trp radicals;[@cit40] our future work will investigate the interaction of hydroxyl radicals with 5′-GMP and the possible photocytotoxicity of **3-\[N1,N3\]**.
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